A plan has been introduced to address the cost of obesity drugs, with the White House striking deals with companies such as Eli Lilly and Novo Nordisk for lower prices. However, the plan's impact on costs and its implementation are uncertain, with some reports indicating it may create new challenges and costs for insurers. The plan's ability to lower drug prices for most patients remains unclear.